

KEYTRUDA[®]

(pembrolizumab) for Injection 50 mg

PRODUCT UPDATE

Dear Customer:

Merck Sharp & Dohme Corp. (Merck), a subsidiary of Merck & Co., Inc., is pleased to announce that KEYTRUDA has been assigned a Level II HCPCS C code, effective 1/1/2015. This code applies to Medicare hospital outpatient claims for dates of service on or after 1/1/2015.

HCPCS CODE	DESCRIPTOR
C9027	Injection, pembrolizumab, 1 mg

HCPCS=Healthcare Common Procedure Coding System.

Medicare Part B reimburses hospital outpatient facilities based on the hospital outpatient prospective payment system (PPS). Please see the Centers for Medicare & Medicaid Services website for specific instructions. Providers are responsible for choosing the appropriate codes when submitting claims. Merck and its agents make no warranties or guarantees, express or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs.

If you have questions about KEYTRUDA, please contact your Merck representative. If you have questions or need additional information about coding and reimbursement related to KEYTRUDA, please contact The Merck Access Program.

The Merck Access Program for KEYTRUDA is available online (www.merckaccessprogram-keytruda.com). You may also call toll-free (855-257-3932) between 8:00 AM and 8:00 PM ET, Monday through Friday.

Sincerely,



Patrick Magri
Senior Vice President, Managed Markets and Policy

Copyright © 2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
All rights reserved. ONCO-1120555-0000 11/14 keytruda.com

